A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

This study is testing a new drug called HC-1119 — a capsule form of a hormone-blocking medication — for men with metastatic prostate cancer whose disease has continued to grow despite having low testosterone levels (castration-resistant prostate cancer), to evaluate how well it works and how safe it is. **You may be eligible if...** - You are a male aged 18 or older - You have been diagnosed with prostate adenocarcinoma confirmed by biopsy or laboratory test - Your cancer has kept growing (PSA rising, new spots on bone scan, or growing tissue lesions) despite hormone therapy (medical or surgical castration) - Your cancer has spread to bone or other organs (confirmed by imaging) - Your testosterone level is very low (castration level) **You may NOT be eligible if...** - You have a small-cell type prostate cancer - You have not yet achieved castration-level testosterone - Your cancer has not shown confirmed progression despite treatment - You have significant health problems that would prevent you from safely participating Talk to your doctor to see if this trial is right for you.